Document is current
Any future updates will be listed below
-
Authors
Höllerhage, Matthias https://orcid.org/0000-0002-5333-0121
Becktepe, Jos
Classen, Joseph
Deuschl, Günther
Ebersbach, Georg
Hopfner, Franziska
Lingor, Paul
Löhle, Matthias
Maaß, Sylvia
Pötter-Nerger, Monika
Odin, Per
Woitalla, Dirk
,
Bähr, Mathias
Berg, Daniela
Brockmann, Kathrin
Buhmann, Carsten
Ceballos-Baumann, Andrés
Claßen, Joseph
Deuschl, Cornelius
Dodel, Richard
Eggers, Carsten
van Eimeren, Thilo
Fanciulli, Alessandra
Fimm, Bruno
Folkerts, Ann-Kristin
Gausepohl, Madeleine
Hasan, Alkomiet
Hermann, Wiebke
Hilker-Roggendorf, Rüdiger
Höglinger, Günter
Jost, Wolfgang
Kalbe, Elke
Kassubek, Jan
Klebe, Stephan
Klein, Christine
Klietz, Martin
Köglsperger, Thomas
Kühn, Andrea
Krack, Paul
Krismer, Florian
Kuhlenbäumer, Gregor
Levin, Johannes
Liepelt-Scarfone, Inga
Loewenbrück, Kai
Lorenzl, Stefan
Maetzler, Walter
Menzel, Regina
Meyer, Philipp T.
Mollenhauer, Brit
Neumann, Manuela
Outeiro, Tiago
Reese, René
Reetz, Kathrin
Rieß, Olaf
Ruf, Viktoria
Schneider, Anja
Schrader, Christoph
Schnitzler, Alfons
Seppi, Klaus
Sixel-Döring, Friederike
Storch, Alexander
Tönges, Lars
van Eimeren, Thilo
Walter, Uwe
Wächter, Tobias
Warnecke, Tobias
Wegner, Florian
Winkler, Christian
Witt, Karsten
Zeuner, Kirsten
Trenkwalder, Claudia
Höglinger, Günter U.
-
Funding
Funding for this research was provided by:
Deutsche Gesellschaft für Neurologie
Klinikum der Universität München
- License Information
-
More Information
Article History
Received: 28 June 2024
Revised: 7 August 2024
Accepted: 9 August 2024
First Online: 29 August 2024
Declarations
:
: Jos Becktepe served as a consultant for Jazz Pharmaceuticals and Neuraxpharm; received honoraria for scientific presentations from Ipsen; received research support from Stratmann; Günther Deuschl served as a consultant for Boston Scientific, Cavion and Insightec; received publication royalties from Thieme; received funding from the German Research Council (SFB 1261, T1) and private foundations. Georg Ebersbach served as a consultant for AbbVie, BIAL, Desitin, STADAa, ESTEVE, Neuraxpharm, Boehringer; received honoraria for scientific presentations from AbbVie, BIAL, Britannia, Desitin, ESTEVE, Licher, STADA, Zambon; received publication royalties from Kohlhammer, Thieme, and Springer. Matthias Höllerhage served as a consultant for AbbVie; received honoraria for scientific presentations from AbbVie; received publication royalties from Thieme. Günter Höglinger has ongoing research collaborations with Roche, UCB, AbbVie; served as a consultant for Abbvie, Alzprotect, Amylyx, Aprinoia, Asceneuron, Bayer, Bial, Biogen, Biohaven, Epidarex, Ferrer, Kyowa Kirin, Lundbeck, Novartis, Retrotope, Roche, Sanofi, Servier, Takeda, Teva, UCB; received honoraria for scientific presentations from AbbVie, Bayer, Bial, Biogen, Bristol Myers Squibb, Esteve, Kyowa Kirin, Pfizer, Roche, Teva, UCB, Zambon. received publication royalties from Academic Press, Kohlhammer, and Thieme. Dirk Woitalla served as a consultant for AbbVie, Bial, Esteve, StadaPharm, Zambone; received honoraria for scientific presentations from AbbVie, Daiichi, Desitin, Esteve, UCB, Zambone. All other authors declared no conflict of interest.
